Antibody-opsonized tumor cells

Antibody-opsonized tumor cells represent a biological state where malignant cells are coated with specific monoclonal antibodies (mAbs) targeting tumor-associated antigens. This opsonization serves as a critical bridge between the adaptive and innate immune systems, as the Fc portion of the bound antibodies is recognized by Fc gamma receptors (FcγRs) on effector cells such as natural killer (NK) cells, neutrophils, and macrophages. This interaction triggers potent anti-tumor effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Additionally, the bound antibodies can activate the classical complement pathway, leading to complement-dependent cytotoxicity (CDC). While not a single molecular target itself, the formation of antibody-opsonized tumor cells is the fundamental mechanism of action for many clinically approved cancer immunotherapies, facilitating the targeted destruction of cancer cells while potentially priming long-term adaptive immune responses through enhanced antigen presentation.

Other names

Antibody-coated tumor cellsIgG-opsonized cancer cells

Therapeutic monoclonal antibodies bind to specific tumor-associated antigens, opsonizing the cell and marking it for destruction by effector immune cells (via Fc receptors) or the complement system.